Company Overview

Stream Biomedical was founded in 2016 to develop a novel therapeutic protein drug to commercialization. The Stream Team is a small group of seasoned biopharma R&D professionals.

Our drug, recombinant human Perlecan Domain V (rhPDV), has been shown to have significant neuroprotective and neuroreparative properties, resulting in dramatic functional improvement when administered after injury to the brain. The initial target therapeutic indication for the rhPDV molecule is the treatment of acute ischemic stroke.

The Unmet Need


Strokes / year US


Strokes / year worldwide

Stroke is one of the most debilitating conditions in human medicine. Only 10% of stroke survivors achieve full recovery, while over 40% are left with moderate to severe impairment, and 10% require long-term residential care. (American Stroke Association)

Our Solution

Recombinant Human Perlecan Domain V (rhPDV)

Perlecan is a large protein that is found in abundance in the extracellular matrix of many tissues and is a key component in the basement membranes of brain vasculature.

Perlecan consists of five domains (I-V), which are in turn comprised of subdomains. Research has shown that endogenous Perlecan Domain V (PDV) is actively generated in response to vigorous activity and trauma, including traumatic brain injury (TBI) & stroke. PDV is a critical component of the body’s ability to self-repair after stroke.

Our rhPDV drug has been has shown in preclinical studies to be neuroprotective; in other words, the molecule protects brain cells and limits the effects of injury once administered.

rhPDV has also been shown to support neurological repair in vivo; it is both angiogenic (helps create new blood vessels) and neurogenic (helps proliferate new “baby” neurons in the brain and fosters them to become functional “adult” neurons).

Most importantly, rhPDV has shown to provide significant post-acute-stroke functional recovery in in vivo stroke models.